Salisbury, United Kingdom

Stephen John Elvin

This inventor holds 2 USPTO granted patents. Top assignees: The Secretary of State for Defence, The Secretary of State of Defence. Active years: 2011-2013.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2011-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Stephen John Elvin: Innovator in Immunogenic Agents

Introduction

Stephen John Elvin, an accomplished inventor based in Salisbury, GB, has made significant contributions to the field of immunogenic agents. With a total of two patents to his name, Elvin's work focuses on creating protective immune responses to combat infections.

Latest Patents

Elvin's latest patents revolve around an innovative immunogenic agent. This agent comprises a killed strain or a combination of components that induce a protective immune response in animals upon administration. The composition includes at least two members selected from a group containing (i) a lipopolysaccharide, (ii) a capsular polysaccharide, and (iii) a protein or its immunogenic variant or fragment. This invention plays a vital role in the prevention and treatment of various infections.

Career Highlights

Stephen John Elvin's professional journey includes pivotal roles at esteemed organizations, such as the Secretary of State for Defence. His experience in these significant institutions has contributed to his research and development in the field of immunology.

Collaborations

Throughout his career, Elvin has collaborated with notable coworkers, including Gareth David Healey and Ethel Diane Williamson. These partnerships have fostered innovation and enhanced the research processes involved in developing his patented inventions.

Conclusion

With a focus on immunogenic agents, Stephen John Elvin continues to be a prominent figure in the realm of scientific innovation. His patents demonstrate a commitment to advancing medical science and improving health outcomes through the development of effective immunological solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…